Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model

• Published in: Antimicrobial agents and chemotherapy Vol. 60; no. 4; pp. 2075 - 2080
• Main Authors: Nicasio, Anthony M, VanScoy, Brian D, Mendes, Rodrigo E, Castanheira, Mariana, Bulik, Catharine C, Okusanya, Olanrewaju O, Bhavnani, Sujata M, Forrest, Alan, Jones, Ronald N, Friedrich, Lawrence V, Steenbergen, Judith N, Ambrose, Paul G
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.04.2016
• Subjects: Anti-Bacterial Agents; Anti-Bacterial Agents - pharmacokinetics; Anti-Bacterial Agents - pharmacology; beta-Lactamase Inhibitors; beta-Lactamase Inhibitors - pharmacokinetics; beta-Lactamase Inhibitors - pharmacology; beta-Lactamases; beta-Lactamases - genetics; beta-Lactamases - metabolism; Computer Simulation; Drug Therapy, Combination; Escherichia coli; Escherichia coli - drug effects; Escherichia coli - genetics; Escherichia coli - metabolism; Experimental Therapeutics; Gene Expression; Microbial Sensitivity Tests; Models, Statistical; Organisms, Genetically Modified; Penicillanic Acid; Penicillanic Acid - analogs & derivatives; Penicillanic Acid - pharmacokinetics; Penicillanic Acid - pharmacology; Piperacillin; Piperacillin - pharmacokinetics; Piperacillin - pharmacology; Plasmids - chemistry; Plasmids - metabolism; Transcription, Genetic

We have previously demonstrated the pharmacokinetic-pharmacodynamic (PK-PD) index best associated with the efficacy of tazobactam when used in combination with ceftolozane to be the percentage of the dosing interval during which tazobactam concentrations remained above a threshold value (%time>th...